Stereotaxis (NYSEAMERICAN:STXS) Issues Quarterly Earnings Results

Stereotaxis (NYSEAMERICAN:STXS) posted its earnings results on Wednesday. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01), FiscalAI reports. The firm had revenue of $7.46 million for the quarter, compared to the consensus estimate of $8.43 million. Stereotaxis had a negative return on equity of 440.00% and a negative net margin of 73.43%.

Stereotaxis Stock Down 15.6%

Shares of Stereotaxis stock traded down $0.45 on Wednesday, hitting $2.41. 851,842 shares of the company’s stock traded hands, compared to its average volume of 464,296. The stock has a market cap of $219.02 million, a P/E ratio of -8.30 and a beta of 1.65. Stereotaxis has a 52-week low of $1.54 and a 52-week high of $3.59. The firm’s 50-day moving average is $2.96 and its 200 day moving average is $2.53.

Institutional Trading of Stereotaxis

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Stereotaxis by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company’s stock worth $10,702,000 after buying an additional 138,482 shares in the last quarter. Geode Capital Management LLC grew its stake in Stereotaxis by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,478,201 shares of the company’s stock valued at $3,135,000 after acquiring an additional 13,891 shares in the last quarter. Rhumbline Advisers lifted its position in Stereotaxis by 223.7% in the 2nd quarter. Rhumbline Advisers now owns 148,913 shares of the company’s stock worth $316,000 after buying an additional 102,916 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in Stereotaxis during the third quarter valued at $413,000. Finally, Jane Street Group LLC bought a new stake in shares of Stereotaxis in the 2nd quarter valued at approximately $78,000. Institutional investors own 45.35% of the company’s stock.

Wall Street Analysts Forecast Growth

STXS has been the subject of several research analyst reports. UBS Group set a $4.00 price objective on Stereotaxis in a research note on Wednesday, November 5th. Roth Capital reissued a “buy” rating and issued a $4.00 price target on shares of Stereotaxis in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $4.00.

Stereotaxis Company Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.